WebJan 25, 2024 · The Limus Eluted from A Durable versus ERodable Stent coating (LEADERS) multicenter noninferiority trial randomized 1707 patients to either the … WebFood and Drug Administration
CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus …
WebOct 9, 2007 · CYPHER, Sirolimus-eluting coronary stent. The E-SIRIUS trial compares restenosis rates between the CYPHER stent and bare metal stents. It is a double blind, multi-center, controlled, randomized trial, involving 352 moderate to high-risk patients from 35 European clinical centers. Five-year follow-up results, which were presented at the … WebMar 3, 2011 · The ISAR-TEST-3 trial enrolled 605 patients randomized to a BIO polymer stent loaded with sirolimus, a sirolimus polymer-free stent and a sirolimus with permanent polymer stent (Cypher; Cordis, Florida, USA). The BIO polymer was completely absorbed within 6 to 9 wk after stent deployment, whereas 100% of sirolimus was released within … normal sinus tachycardia heart rate
CYPHER(TM) Sirolimus-Eluting Coronary Stent Demonstrates …
WebCordis Corporation recently announced that it has received CE mark approval for the treatment of acute myocardial infarction (AMI) using the CYPHER® SELECT™ PLUS sirolimus-eluting coronary stent. CE marking means conformity to the applicable European Directive, and in the specific context of AMI permits the CYPHER stent to be placed on … WebSirolimus is a macrolide antibiotic with a cytostatic mechanism and an anti-inflammatory effect. Paclitaxel is a chemotherapeutic (cytotoxic) agent. The delivery platform is … WebApr 20, 2005 · MIAMI, April 20, 2005 /PRNewswire-FirstCall via COMTEX/ -- Cordis Corporation, a Johnson & Johnson company, today announced that the U.S. Food and Drug Administration (FDA) has approved a condition of use for the CYPHER(R) Sirolimus-eluting Coronary Stent, allowing patients receiving the stent to immediately undergo Magnetic … how to remove sharpie ink from leather